Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    "Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Show Display Options
RSS Create an RSS feed from your search for:
"Camurati-Engelmann disease" [DISEASE] OR NCT00001754 [ID-NUMBER]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Skeletal Disorders and Short Stature
Conditions: Developmental Bone Disease;   Dwarfism;   Skeletal Dysplasias
Intervention:
2 Completed Angiotensin II Antagonism of TGF-Beta 1
Conditions: Diabetic Nephropathy;   Hypertension
Intervention: Drug: Candesartan
3 Recruiting TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
Condition: EBV-positive Nasopharyngeal Carcinoma
Interventions: Genetic: DNR.NPC-specific T cells;   Genetic: DNR.NPC-specific T cells + cyclophosphamide + fludarabine
4 Active, not recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
5 Completed Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administration in Healthy Volunteers
Condition: Healthy
Interventions: Drug: P144 cream;   Drug: Placebo
6 Withdrawn Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome
Condition: Marfan Syndrome
Intervention: Other: Blood draw
7 Recruiting Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects
Condition: Hypertension
Intervention:
8 Completed Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
Conditions: Pancreatic Neoplasms;   Melanoma;   Colorectal Neoplasms
Intervention: Drug: AP 12009
9 Recruiting Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2);   Behavioral: Questionnaires
10 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
11 Recruiting Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Enzalutamide;   Drug: LY2157299
12 Completed Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma
Condition: Asthma
Intervention: Drug: montelukast
13 Active, not recruiting Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)
Conditions: Lymphoma;   Hodgkin's Disease;   Relapse;   Lymphoma, Non-Hodgkin
Intervention: Genetic: TGFbeta resistant LMP-specific CTLs
14 Recruiting TGF-(Beta) and Susceptibility to RSV
Conditions: Respiratory Syncytial Virus;   Asthma
Intervention:
15 Completed Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Conditions: Glioblastoma;   Anaplastic Astrocytoma
Interventions: Drug: AP 12009 10 µM;   Drug: AP 12009 80 µM;   Drug: temozolomide or PCV;   Device: Drug delivery system for administration of AP 12009;   Procedure: Placement of Drug Delivery System
16 Terminated
Has Results
Anti-TGF-beta Therapy in Patients With Myelofibrosis
Conditions: Myelofibrosis;   Primary Myelofibrosis;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Post-essential Thrombocythemia Related Myelofibrosis
Intervention: Biological: monoclonal antibody to TGF-beta
17 Recruiting SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-Small Cell Lung Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma
Interventions: Biological: Fresolimumab;   Other: Pharmacological Study;   Radiation: Stereotactic Body Radiation Therapy
18 Completed Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Lung Cancer;   Prostate Cancer
Interventions: Procedure: venipuncture;   Radiation: radiation therapy
19 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
20 Not yet recruiting ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
Condition: Rectal Adenocarcinoma
Interventions: Drug: LY2157299;   Drug: Capecitabine;   Drug: Fluorouracil;   Procedure: Tumor specific mesorectal excision

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.